头部中药企业增收不增利,加码研发创新寻求破局

21财经
Sep 05

2025年上半年,中药行业在政策推动、价格调整、技术革新与需求分化的交织中,呈现出结构性机遇的发展格局。多家企业在变革中交出了半年报,几家欢喜几家愁。21世纪经济报道记者梳理了A股中药市值前五企业的业绩,发现“增收不增利”的整体特征较为突出,另外企业间也存在两极分化。其中,云南白药实现营收净利双增,片仔癀则实现双降,另外,白云山、华润三九、同仁堂实现增收不增利。从营收来看,白云山以418.35亿元...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10